Categories: News

SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to Cantor at corporateaccess@cantor.com or KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

For more information, please contact:

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276

Staff

Recent Posts

Horizon Technology Finance Provides First Quarter 2024 Portfolio Update

- HRZN Originates $33.5 Million of New Loans in Q1 - - HRZN Ends Quarter…

1 hour ago

ZoomCare Selects athenahealth to Fuel Growth, Increase Efficiency, Facilitate High-Quality Care, and Improve Patient Experience

athenahealth’s cloud-based suite of EHR, RCM, and patient engagement solutions empowers ZoomCare to scale and…

7 hours ago

Cedars-Sinai Launches Virtual Healthcare for Children and Spanish Speakers

Cedars-Sinai Connect Expands Virtual Healthcare Services After Initial Success Treating Thousands of California AdultsLOS ANGELES--(BUSINESS…

7 hours ago

Innovaccer Launches AI-Assisted Quality Management Solution for ACOs to Meet Electronic Quality Reporting Requirements

Enhanced AI and analytics capabilities will help ACOs meet eCQM guidelines and navigate the changes…

7 hours ago

ASTCT Supports the FDA’s Approval of Earlier Use of CAR T-Cell Therapy for Multiple Myeloma

The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and…

7 hours ago

From Kids to Robots: Senzime Secures Multiple Top-Rated US Hospital Deals

UPPSALA, SWEDEN / ACCESSWIRE / April 10, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF), an industry leader in…

7 hours ago